Deferred Revenue

12 Months Ended

Dec. 31, 2018

Revenue from Contract with Customer [Abstract]

Deferred Revenue

Deferred Revenue

Deferred revenue consists of the following:

	As of December 31,
	2018		2017
Current portion:
Received or receivable from Sanofi (see Note 3a)	$	246.7	$	177.7
Received or receivable from Bayer (see Note 3b)	44.4		39.0
Received or receivable from Teva (see Note 3c)	92.5		43.5
Other	68.9		59.9
	$	452.5	$	320.1
Long-term portion:
Received or receivable from Sanofi (see Note 3a)	$	279.3	$	379.9
Received or receivable from Bayer (see Note 3b)	45.1		29.7
Received or receivable from Teva (see Note 3c)	102.0		153.9
Other	37.8		65.7
	$	464.2	$	629.2